Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Hypoxia-guided Radiotherapy in SCLC
NCT01210131Phase 2Withdrawn
- Sponsor
- Maastro Clinic
- Start
- Jul 2013
- Primary completion
- Jan 2014
- Modality
- Radiopharmaceutical
01
Overview
Phase 2, open-label, single-arm trial of Flortanidazole F-18 in small cell lung cancer (SCLC), sponsored by Maastro Clinic. Primary endpoint: Cumulative local progression at 18 months. Planned start Jul 2013; status: withdrawn.
02
Drugs
Flortanidazole F-18
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01210131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01210131.